BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

BioPharma Drug Discovery

RenovoRx and Imugene Join Forces for Oncolytic Virus Therapy Using TAMP Platform

Collaboration will explore trans-arterial delivery of Imugene's CF33 oncolytic virus utilizing RenovoRx's TAMP therapy platform TAMP enables localized, ...

July 25, 2023 | News

China's Mabwell Announces NMPA Approval of Novel B7-H3 ADC (7MW3711) for IND

B7-H3 is a member of the B7 ligand family and is overexpressed in most cancer types but expressed at a low level in normal tissues. In malignant tissues, B...

July 24, 2023 | News

Insilico Medicine Nominates Preclinical Candidate for ISM001-055, First Generative AI IPF Drug

Insilico Medicine merges nebulizer device with AI-driven drug discovery; Potential advantages for the inhalation solution include a smaller effe...

July 24, 2023 | News

AstraZeneca's Saphnelo Now Available in Malaysia for Adult Autoantibody-Positive SLE

SLE is a chronic and complex autoimmune condition that can affect any organ, and patients often experience inadequate disease control, long-term organ dama...

July 21, 2023 | News

US FDA Grants Orphan Drug Designation to SN Bioscience's 'SNB-101' for Small Cell Lung Cancer

SNB-101 showed excellent efficacy in animal small cell lung cancer models, and based on this, it has been designated as an orphan drug by the US FDA after ...

July 21, 2023 | News

Scribe Therapeutics and Sanofi Team Up to Advance In Vivo Genetic Medicines for Sickle Cell and Genomic Disease

Predicated on the progress of the companies’ first collaboration, Sanofi has selected Scribe’s novel CRISPR by Design™ approach to driv...

July 18, 2023 | News

GeneQuantum and InxMed Partner for Innovative ADC Drug Research

According to the agreement, GeneQuantum will provide InxMed with its independently developed, globally leading technologies in site-specific glycan conjuga...

July 17, 2023 | News

Antengene's XPOVIO® Approved in Hong Kong for Relapsed Multiple Myeloma

XPOVIO® has received regulatory approvals in 41 countries and regions including the United States, Israel, the United Kingdo...

July 17, 2023 | News

Biosyngen's First-in-class Cell Therapy BRG01 Receives FDA Fast Track Designation

Fast Track Designation (FTD) aims to facilitate the development of drugs targeting severe or life-threatening diseases that have the potential to a...

July 12, 2023 | News

Transcenta Receives Approvals for Global Phase III Trial of Osemitamab (TST001)

To initiate TranStar 301 global Phase III pivotal trial of Osemitamab (TST001) in combination with Nivolumab and chemotherapy for the first-line treatment ...

July 10, 2023 | News

Hexvix® Completes Phase III Bridging Trial Enrollment for Bladder Cancer

The study is a prospective, self-controlled, multicenter Phase Ⅲ trial aimed at investigating the additional detection rate and safety of Hexvix®&nbs...

July 10, 2023 | News

SK Bioscience and Government Pharmaceutical Organization Strengthen Vaccine Infrastructure in Thailand

SK bioscience and the Government Pharmaceutical Organization agreed to establish a pandemic response platform, encompassing not only Thailand but extendi...

July 05, 2023 | News

FDA Approves Cu-64 SAR-bisPSMA Phase III Trial for Prostate Cancer

FDA agreement for a pivotal Phase III trial for 64Cu SAR-bisPSMA diagnostic in prostate cancer Phase III trial design based on&n...

July 05, 2023 | News

Innovent and IASO Bio Receive NMPA Approval for FUCASO®, a Fully-human BCMA CAR-T Therapy for Multiple Myeloma

Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality me...

July 03, 2023 | News

Stay Connected